Ratings by Oppenheimer (Les Sulewski)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/9/2026 | Teva Pharma | TEVA | Maintain | Outperform (N/A) |
|
Details | ||
| 10/8/2026 | Pacira Pharmaceuticals | PCRX | Downgrade | Perform (Outperform) |
25.20 (36.36) |
44.29% | Details | |
| 9/23/2026 | Inova Technology, Inc. | INVA | New Coverage | Outperform (N/A) |
20.98 (21.03) |
0.24% | Details | |
| 9/23/2026 | Amneal Pharmaceuticals | AMRX | New Coverage | Outperform (N/A) |
19.50 (19.42) |
-0.41% | Details | |
| 9/23/2026 | Teva Pharma | TEVA | New Coverage | Outperform (N/A) |
39.52 (41.45) |
4.88% | Details | |
| 9/23/2026 | Collegium Pharmaceutical | COLL | New Coverage | Outperform (N/A) |
22.78 (23.36) |
2.55% | Details | |
| 9/23/2026 | CorMedix | CRMD | New Coverage | Outperform (N/A) |
7.78 (7.39) |
-5.01% | Details | |
| 9/23/2026 | Pacira Pharmaceuticals | PCRX | New Coverage | Outperform (N/A) |
24.70 (25.20) |
2.02% | Details | |
| 9/23/2026 | Vanda Pharmaceuticals | VNDA | New Coverage | Outperform (N/A) |
5.21 (4.09) |
-21.5% | Details | |
| 9/23/2026 | Viatris | VTRS | New Coverage | Outperform (N/A) |
130.31 (18.27) |
-85.98% | Details | |
| 9/23/2026 | ANI Pharmaceuticals | ANIP | New Coverage | Perform (N/A) |
77.91 (72.69) |
-6.7% | Details |
